Vandetanib (Caprelsa)
- Status:
- Red
- Decision Date:
- March 2023
Comments
Treatment of aggressive and symptomatic rearranged during transfection (RET) mutant medullary thyroid cancer in patients aged ≥5 years with unresectable locally advanced or metastatic disease. NHSE commissioned.Red Drug Classifications
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again